Cargando…
Implementing Keytruda/Pembrolizumab Testing in Clinical Practice
This Commentary addresses the FDA approval of pembrolizumab and the changes necessary in clinical practice to identify patients who would benefit from such treatment.
Autores principales: | Ratner, Dmitry, Lennerz, Jochen K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067935/ https://www.ncbi.nlm.nih.gov/pubmed/29523645 http://dx.doi.org/10.1634/theoncologist.2017-0591 |
Ejemplares similares
-
Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016) -
The Need And Benefit of Implementing Telemedicine in Clinical Practice
por: Burguera, Bartolome, et al.
Publicado: (2020) -
Congenital toxoplasmosis: the importance of implementing clinical practice guidelines
por: Amendoeira, Maria Regina Reis, et al.
Publicado: (2021) -
Exploring the Skin Brain Link: Biomarkers in the Skin with Implications for Aging Research and Alzheimer’s Disease Diagnostics
por: Klostermeier, Stefanie, et al.
Publicado: (2023) -
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)